Bacillus subtilis MB40 and No Observed Adverse Effect Level

• Safety Assessment of Bacillus subtilis MB40 for Use in Foods and Dietary Supplements

  • 2021-02-25
  • Clinical Trial
  • Nutrients 13(3)
  • • Jessica L. Spears
    • R. Kramer
    • A. Nikiforov
    • Marisa O. Rihner
    • E. A. Lambert

  • PubMed: 33668992
  • DOI: 10.3390/nu13030733

  3 Insights on

  • No Observed Adverse Effect Level

  • High evidence

  In rats, the no-observed-adverse-effect level (NOAEL) for MB40 after repeated oral administration for 14 days was determined to be 2000 mg/kg bw/day

  Effect

  Neutral

  Effect size

  Small